Cortinovis Diego, Bidoli Paolo, Canova Stefania, Colonese Francesca, Gemelli Maria, Lavitrano Maria Luisa, Banna Giuseppe Luigi, Liu Stephen V, Morabito Alessandro
Department Medical Oncology-ASST-Monza Ospedale San Gerardo, via Pergolesi 33, 20090 Monza, Italy.
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Cancers (Basel). 2021 Mar 8;13(5):1152. doi: 10.3390/cancers13051152.
Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum-etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.
小细胞肺癌（SCLC）是最致命的胸部肿瘤之一，部分原因是其快速的倍增时间和早期转移扩散。从历史上看，由铂类-依托泊苷或蒽环类药物组成的细胞毒性化疗方案已显示出较高的缓解率，但早期化疗耐药导致晚期SCLC的预后较差。只有一小部分局限性疾病患者可以通过放化疗治愈。鉴于晚期SCLC令人失望的生存率，人们急切期待新的细胞毒性药物。不幸的是，近几十年来几乎没有开发出新的化疗药物。本综述描述了用于SCLC的新型化疗药物的研究结果及其在临床实践中的潜在应用。
